Navigation Links
Cardio3 BioSciences Publishes the Science Basis for C-Cure(R) in JACC
Date:8/16/2010

e="border:0px" alt="Click to view news release full screen">  

Cardio3 BioSciences Publishes the Science Basis for C-Cure(R) in JACC

 

MONT-SAINT-GUIBERT, Belgium, August 16, 2010 /PRNewswire/ --

- Article Described a Landmark Process Generating Cardiac Precursor Cells to Rebuild Heart Tissue

Cardio3 BioSciences, a leading Belgian biotechnology company specialising in regenerative therapies for the treatment of cardiovascular disease, today announces that the key scientific work underlying its lead pharmaceutical product C-Cure(R), a revolutionary stem cell treatment for heart failure, has been published in the Journal of the American College of Cardiology (JACC). The findings were described as "landmark work" in the accompanying editorial in today's publication(1).

The research, carried out at Mayo Clinic in Rochester, Minnesota, USA, and in collaboration with the Cardiovascular Center in Aalst, Belgium led to the development of Cardio3 BioSciences' technological platform designed to reprogram the patient's own stem cells to rebuild the heart.

In this ground-breaking work, researchers were able to identify a process involving a cocktail of growth factors to successfully reprogram mesenchymal (connective tissue) stem cells (MSCs) harvested from the bone marrow of heart failure patients into cardiac precursor cells.

Injected into an animal model of heart disease, these cardiac precursor cells improved heart function by repopulating scar tissue and generating new blood vessels, effectively eliminating the scar and rebuilding the heart with new functional human heart tissue. Treated animals demonstrated improved heart function and were cured from their heart failure.

In their editorial, Eduardo Marban, M.D., Ph.D., and Konstantinos Malliaras, M.D., of Cedars-Sinai Heart Institute, describe the
'/>"/>

SOURCE Cardio3 BioSciences
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8

Related biology technology :

1. Cardio3 BioSciences Reports Positive Three-Month Data From its Clinical Trial of C-Cure(R) in Heart Failure
2. Cardio3 BioSciences Completes Patient Enrolment in First Stage of Pivotal Trial of C-Cure(R) in Heart Failure
3. Cardio3 BioSciences Presents Update on C-Cure(R) Second Generation Stem Cell Therapy for Heart Failure at European Society of Cardiology Congress
4. Signum Biosciences Names Braham Shroot as Chief Executive Officer
5. YM BioSciences announces conclusion of Phase I dose-escalation and expansion of ongoing CYT387 Phase I/II clinical study
6. CORRECTED: Ampio Pharmaceuticals Announces Completion of Negotiations for Acquisition of DMI BioSciences, Inc.
7. Ambit Biosciences Announces Transition in Company Leadership
8. Sangamo BioSciences Announces Second Quarter 2010 Conference Call and Webcast
9. Calithera Biosciences Closes $40 Million in Series A Financing
10. MD Biosciences Offers Occlusion-induced Myocardial Infarct Model for Investigating the Cardio-protection of a Drug Treatment in the Event of Ischemia/reperfusion Injury
11. Neurocrine Biosciences Announces Conference Call and Webcast on Worldwide Agreement With Abbott on Elagolix
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/24/2014)... (PRWEB) December 23, 2014 Nashville Fertility ... was elected treasurer for the American Society for Reproductive ... knowledge and research in reproductive medicine. In his ... seat on the executive board and will have a ... Dr. Hill has actively supported ASRM since 1984 when ...
(Date:12/24/2014)... 23, 2014 China Biologic Products, Inc. ... leading fully integrated plasma-based biopharmaceutical company in ... majority-owned subsidiary, Shandong Taibang Biological Products Co. Ltd., ... the China Food and Drug Administration (the "CFDA") ... previously disclosed in the Company,s public filings, the ...
(Date:12/24/2014)... 2014 Sigma-Aldrich Corporation (NASDAQ: ... under the Hart-Scott-Rodino Antitrust Improvements Act (HSR Act) ... 22, 2014, thereby completing the U.S. HSR Act ... of the Company by Merck KGaA, Darmstadt, Germany.  ... condition to closing the transaction, which remains subject ...
(Date:12/22/2014)... 22, 2014 The Center for ... of technical training across the life sciences industry, has ... (SCDM) to provide the organization's members with discounted ... access to the more than 350 sessions across 80 ... 10% off when registering for a public course ...
Breaking Biology Technology:Nashville Fertility Center Announces Dr. George A. Hill Selected to Serve as ASRM Treasurer for 2014-15 2Nashville Fertility Center Announces Dr. George A. Hill Selected to Serve as ASRM Treasurer for 2014-15 3China Biologic Receives GMP Certification for New Coagulation Factor Facility 2China Biologic Receives GMP Certification for New Coagulation Factor Facility 3Acquisition of Sigma-Aldrich by Merck KGaA, Darmstadt, Germany, Receives U.S. Antitrust Clearance 2Acquisition of Sigma-Aldrich by Merck KGaA, Darmstadt, Germany, Receives U.S. Antitrust Clearance 3CfPIE Announces Partnership with the Society for Clinical Data Management 2CfPIE Announces Partnership with the Society for Clinical Data Management 3
... July 8 Cornerstone Therapeutics Inc. (Nasdaq: ... special meeting of its stockholders on August 27, 2009. ... will be asked to approve a series of amendments ... implement governance arrangements and provide Chiesi Farmaceutici SpA with ...
... SAN DIEGO, July 8 Biomatrica today announced that ... SampleMatrix room temperature storage technology to archive its DNA ... SampleMatrix technology in place of ultra-low-temperature freezers for the ... SMGF will move its collection of previously archived samples ...
... Researchers at Cellular Dynamics ... pluripotent stem cells, which have the ability to generate all ... ordinary human blood samples. This significant breakthrough provides a readily ... samples in storage at blood repositories and healthcare institutions worldwide. ...
Cached Biology Technology:Cornerstone Therapeutics Inc. Announces Record Date and Meeting Date for Special Meeting of Stockholders for Vote with Respect to Charter Amendments 2Cornerstone Therapeutics Inc. Announces Record Date and Meeting Date for Special Meeting of Stockholders for Vote with Respect to Charter Amendments 3Cornerstone Therapeutics Inc. Announces Record Date and Meeting Date for Special Meeting of Stockholders for Vote with Respect to Charter Amendments 4Cornerstone Therapeutics Inc. Announces Record Date and Meeting Date for Special Meeting of Stockholders for Vote with Respect to Charter Amendments 5Sorenson Molecular Genealogy Foundation to Protect Archived DNA Using Biomatrica's Room Temperature Storage 2Sorenson Molecular Genealogy Foundation to Protect Archived DNA Using Biomatrica's Room Temperature Storage 3Cellular Dynamics International Reprograms Blood Cells into Stem Cells 2
(Date:12/19/2014)... 18, 2014  23andMe, Inc., the leading personal genetics ... pinpoints fine-scale differences in genetic ancestry of individuals from ... Since immigrants first arrived more than four hundred ... has served as a meeting place for peoples from ... the ongoing mixing of peoples with African, European, and ...
(Date:12/17/2014)... , Dec. 16, 2014 Valencell, a leader ... PerformTek biometric technology to industry leaders such as Intel, ... clinically validated, biometric wearable products. These products will be ... Las Vegas . ... accurate, flexible and robust – with the clinical data ...
(Date:12/11/2014)... --Research and Markets , ... ) has announced the addition of the ... their offering. One major trend ... multimodal biometric systems. Multimodal biometric systems utilize more ... and identification purposes. This helps to reduce the ...
Breaking Biology News(10 mins):23andMe Study Sketches Genetic Portrait of the United States 223andMe Study Sketches Genetic Portrait of the United States 323andMe Study Sketches Genetic Portrait of the United States 4Valencell PerformTek Biometrics Power the Most Accurate Wearables at CES 2015 2Biometrics Market in India 2015-2019: Key Vendors are 3M Cogent, NEC, Safran and Suprema 2
... has been shown to cause pain by exciting the ... and the hot, spicy ingredient in chili peppers, UCSF ... plants and animals have evolved the same molecular strategy ... specific receptor on sensory nerves. The research provides new ...
... hold promise for reducing the destruction of dopaminergic cells ... lost to the disease, scientists say. , Research ... Neuroscience shows a human neural stem cell transplant essentially ... normally rather than displaying the progressive loss of movement ...
... discovered that mutations in a gene known as SOS1 ... common childhood genetic disorder which occurs in one in ... stature, facial abnormalities, and learning disabilities, as well as ... Led by researchers at Harvard Medical School-Partners Healthcare ...
Cached Biology News:Tarantula venom and chili peppers target same pain sensor 2Transplanted brain cells hold promise for Parkinson's disease 2Transplanted brain cells hold promise for Parkinson's disease 3Study uncovers mutation responsible for Noonan Syndrome 2
Gentamicin sulfate, 5g...
E2F2 protein...
Rabbit Anti-melatonin (different linkage) Polyclonal Antibody...
Anti-ACTH Immunogen: Porcine ACTH conjugated to BSA. Available Date: 38566...
Biology Products: